ING on how life sciences hits the sweet spot

Rising interest rates and sluggish dealflow may be concerns, but there are still notable opportunities in emerging asset classes and energy transition financing, say ING’s Arie Hubers and Pierre Devlaminck.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this